Online inquiry

IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6637MR)

This product GTTS-WQ6637MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ITGAV gene. The antibody can be applied in Ovarian Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001144999.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3685
UniProt ID P06756
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6637MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12691MR IVTScrip™ mRNA-Anti-DLL4, OMP-21M18(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA OMP-21M18
GTTS-WQ6168MR IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CP-751871
GTTS-WQ12287MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MSB-0010718C
GTTS-WQ10734MR IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA M-281
GTTS-WQ14797MR IVTScrip™ mRNA-Anti-CD70, SGN-70(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-70
GTTS-WQ15088MR IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ST2146
GTTS-WQ9391MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Interleukin 2
GTTS-WQ13032MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Peg-IFNA2 R23
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW